MedTrace Logo

Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C

NCT04463901 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2020-07-09

No results posted yet for this study

Summary

The purpose of this randomized clinical trial is to compare the efficacy and safety of intraoperative mitomycin C(MMC) combined with limbal conjunctival autograft(LCAG) or conjunctival autograft(CAG) for recurrent pterygium surgery. The investigators will also evaluate particular risk factors related to pterygium recurrence

Conditions

  • Recurrent Pterygium

Interventions

PROCEDURE

Pterygium excision

Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.

PROCEDURE

Intraoperative mitomycin C

Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.

PROCEDURE

Conjunctival autograft

A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.

PROCEDURE

Limbal conjunctival autograft

A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Zhou Shiyou, M.D., Ph.D. · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04463901 on ClinicalTrials.gov